Canada markets open in 5 hours 50 minutes

Aequus Pharmaceuticals Inc. (AQS.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.03000.0000 (0.00%)
At close: 11:39AM EDT
Full screen
Previous Close0.0300
Open0.0350
Bid0.0250 x 0
Ask0.0300 x 0
Day's Range0.0250 - 0.0350
52 Week Range0.0100 - 0.0550
Volume371,428
Avg. Volume182,359
Market Cap3.979M
Beta (5Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateAug 27, 2024 - Sept 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    Aequus Pharmaceuticals Full Year 2023 Earnings: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)

    Aequus Pharmaceuticals ( CVE:AQS ) Full Year 2023 Results Key Financial Results Revenue: CA$254.9k (down 82% from FY...

  • GlobeNewswire

    Aequus Reports Second Quarter 2023 Financial Highlights and General Update

    VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter ended June 30, 2023 (“Second Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. Doug Janzen shares that “we are very optimistic w

  • GlobeNewswire

    Aequus Announces Zimed PF Now Available in Canada

    VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today, we are thrilled to announce the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. "This marks a new growth phase for Aequus and the launch of a Preservative Free (PF) innovation that brings value to both physicians and patients in a large ther